Despite current headwinds like tariffs and patent expirations, I see long-term opportunity in top-tier pharmaceutical stocks ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr. Jan Lundberg.

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations. Management raised 2025 guidance to ranges of $60 billion-$62 billion in revenue ...

Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...

The analysis also found no statistically significant difference in the risk of NAION—non-arteritic anterior ischaemic optic ...